Compare DexCom, Inc. (DXCM) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wix.Com Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: DexCom, Inc. is far larger — about 10.2× Wix.Com Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Wix.Com Ltd for 62 Days on average.
| DXCM | WIX | |
|---|---|---|
Market Cap | $31.86B | $3.11B |
Volume | 3,607,070 | 809,286 |
Sector | Health | Technology |
52-Week High | $92.34 | $145.54 |
52-Week Low | $54.84 | $40.43 |
Typical Hold Time | 62 Days | 62 Days |
Enterprise Value | $31.32B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
WIX stock trades at $74.13, up 1.59% today, with a neutral technical signal and bullish moving averages. Revenue grew to $1.99B in 2025, but net income margin is negative at -8.19%. The company faces a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026. Analyst consensus is a Buy with a $77.00 price target, though valuation ratios like P/E of 62.84 appear elevated.
The outlook is mixed: strong revenue growth and positive cash flow from operations support the bullish analyst stance, but legal risks and negative profitability margins pose significant headwinds. Upside depends on sustained earnings beats and resolution of litigation, while downside risks include prolonged negative margins and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
